Lexicon Pharma (LXRX) Misses Q3 EPS by 2c

Lexicon Pharma (NASDAQ: LXRX) reported Q3 EPS of ($0.18), $0.02 worse than the analyst estimate of ($0.16). Revenue for the quarter came in at $1.75 million versus the consensus estimate of $2.92 million.

For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.

You May Also Be Interested In

• Corporación América Airports S.A. (CAAP) Misses Q2 EPS by 18c
• Keysight Technologies (KEYS) Tops Q3 EPS by 59c; Offers Guidance
• Gaming and Leisure (GLPI) Reiterated at Market Outperform by Citizens